2Hz-Electroacupuncture Attenuates Conditioned Cue-Evoked Heroin-Seeking Behavior and Increase CB2-Rs Expression in Relapse-Relevant Brain Regions in Heroin-Addicted Rats

Abstract:

In order to investigate the influence of electroacupuncture on heroin seeking behavior and the expression of CB2-Rs in the relapse-relevant brain regions, heroin self-administration rat model which represents the heroin relapse behaviors was developed with progressive fixed ratio program. The model rats were randomly divided into 3 groups: control group, heroin-addicted group and 2Hz electroacupuncture group (stimulating on acupoints zusanli and sanyinjiao). The expression of CB2-Rs in the relapse-relevant brain regions were assessed with immunohistochemistry technologies. The reinstatement of heroin seeking behavior induced by conditioned cue priming showed that compared with the heroin-addicted group, active pokes in the 2Hz electroacupuncture group decreased significantly (p<0.05). Compared with the control group, the expression of CB2-Rs in prefrontal cortex (PFC) and nucleus accumbens (NAc) was significantly decreased (p<0.05) in heroin-addicted group and increaseed significantly recover (p<0.05) in the 2Hz electroacupuncture group. Our present results showed that 2Hz-electroacupuncture could attenuate the conditioned cue-evoked heroin-seeking behavior and the inhibitory effect was mediated partially by the increase CB2-Rs expression in relapse-relevant brain regions in heroin-addicted rats.

• Periodical: Advanced Materials Research (Volumes 998-999)
• Pages: 164-168
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.998-999.164
• Online since: July 2014
• Authors: Lin Chen*, Bao Miao Ma, Kai Yue, Qin Ru, Xiang Tian, Qi Xiong, Lu Liu, Chao Ying Li
• Keywords: 2Hz-Electroacupuncture, CB2-Rs, Conditioned Cue-Evoked Heroin-Seeking Behavior, Heroin-Addicted Rats

References

[1] Kosten, T.R. and P.G. O'Connor. N Engl J Med, 348(2003): pp.1786-1795.

[2] Tang, Y.L. and W. Hao. Addiction, 102(2007): pp.1057-1063.

[3] Cui, C.L., L.Z. Wu and J.S. Han. Neurosci Lett, 295(2000): pp.45-48.

[4] Wen, H.L. and S.W. Teo. Xianggang Hu Li Za Zhi, 19(1975): pp.33-35.

[5] Clement-Jones, V., McLoughlin, L., Lowry, P.J. et al. Lancet, 2(1979): pp.380-383.

[6] Shwartz, M., Saitz, R., Mulvey, K. et al. J Subst Abuse Treat, 17(1999): pp.305-312.

[7] Wu, L.Z., Cui, C.L., Tian, J.B. et al. Brain Res, 851(1999): pp.290-296.

[8] Shi, X.D., Ren, W., Wang, G.B. et al. Brain Res, 981(2003): pp.23-29.

[9] Koob, G.F. Trends Pharmacol Sci, 13(1992): pp.177-184.

[10] Nestler, E.J. Neuropharmacology, 47(2004) Suppl 1: pp.24-32.

[11] Xi, Z.X., Peng, X.Q., Li, X. et al. Nat Neurosci, 14(2011): pp.1160-1166.

[12] Yue, K., Ma, B., Ru, Q. et al. Pharmacol Biochem Behav, 102(2012): pp.1-5.

[13] Hnasko, T.S., B.N. Sotak and R.D. Palmiter. Nature, 438(2005): pp.854-857.

[14] Kim, M.R., Kim, S.J., Lyu, Y.S. et al. Neurosci Lett, 387(2005): pp.17-21.

[15] Bayewitch, M., Avidor-Reiss, T., Levy, R. et al. FEBS Lett, 375(1995): pp.143-147.